Summary
Quest Diagnostics Incorporated (DGX) reported its third-quarter and year-to-date results for the period ending September 30, 2013. While net revenues saw a slight decrease compared to the prior year, the company achieved a significant increase in income from continuing operations, primarily driven by a substantial one-time gain from the sale of royalty rights related to Ibrutinib. This gain significantly boosted profitability for the period. The company also continued to execute its "Invigorate" cost-reduction program and engaged in substantial share repurchases, demonstrating a focus on both operational efficiency and returning value to shareholders. Despite market headwinds impacting healthcare utilization and reimbursement pressures, Quest Diagnostics maintained its leading market position. The company has strategically divested certain non-core assets (like Enterix) and completed several acquisitions (UMass, ATN, Dignity, and ConVerge) to refine its business portfolio and expand its reach. Investors should note the impact of these strategic transactions and the ongoing cost-saving initiatives on the company's financial performance.
Financial Highlights
53 data points| Revenue | $1.79B |
| Cost of Revenue | $1.09B |
| Gross Profit | $699.00M |
| SG&A Expenses | $423.00M |
| Operating Expenses | $1.10B |
| Operating Income | $689.00M |
| Net Income | $405.00M |
| EPS (Basic) | $2.70 |
| EPS (Diluted) | $2.68 |
| Shares Outstanding (Basic) | 150.00M |
| Shares Outstanding (Diluted) | 151.00M |
Key Highlights
- 1Net revenues for the nine months ended September 30, 2013, decreased by 3.9% to $5.4 billion compared to the prior year, while the third quarter saw a 1.9% decrease to $1.8 billion.
- 2Income from continuing operations significantly increased by 154.1% to $402.7 million for the third quarter and by 36.9% to $670.9 million for the nine months, largely due to a $474.1 million pre-tax gain from the sale of royalty rights (Ibrutinib).
- 3Earnings per diluted share from continuing operations rose to $2.66 for the third quarter and $4.32 for the nine months, up from $0.98 and $3.04 respectively in the prior year periods.
- 4The company continues to execute its 'Invigorate' cost-reduction program, aiming for $600 million in annual run-rate cost savings by the end of 2014, with over $250 million expected in realized savings for 2013.
- 5Significant share repurchase activity occurred, with $994 million spent on treasury stock purchases in the first nine months of 2013, funded in part by proceeds from asset sales.
- 6Quest Diagnostics completed several strategic acquisitions, including UMass Memorial Medical Center, Advanced Toxicology Network (ATN), and Dignity Health, and subsequently acquired ConVerge Diagnostic Services in October 2013, indicating continued portfolio optimization.
- 7The company reported a $39.6 million pre-tax loss on the sale of its Enterix business in September 2013, which was not classified as discontinued operations due to continuing involvement.